Peaches Biotech Receives 1.5M from the Government for Two Advanced Projects

The Spanish biotech company Peaches Biotech has raised €1.5 million, non-refundable, from the Government for two of its advanced therapy projects, according to Juan Carlos de Gregorio, CEO of Peaches Biotech.

Specifically, the State Research Agency (AEI) of the Ministry of Science and Innovation has approved funding for a project related to cell therapies against pancreatic cancer and another on tumor labeling with immunotoxins.

Peaches Biotech’s first project is the development of an investigative adoptive cell therapy product opTcells for patients with gastrointestinal cancer. The initiative receives €636,818. 

The Spanish company leads a consortium in which companies from the group itself and public centers collaborate, such as the Health Research Institute of the Hospital 12 de Octubre. In this project, the objective is to generate autologous T cells from peripheral blood, to combat the patient’s own gastrointestinal tumor.

Born2Invest is a digital media website covering the biotech industry, among others. Our companion app allows you to get your daily dose of financial news from industries like banking, cannabis, and innovation in biotechnology.

Peaches Biotech hopes to carry out a phase I clinical trial in cancer patients

The second selected project is tumor labeling with granulysin-based immunotoxins and receives €945,669. In this case, the participating companies of the Peaches Biotech group collaborate with the University of Zaragoza.

The objective is to carry out a phase I clinical trial in cancer patients, selected by systemic injection of immunotoxins, which have already been successful in preclinical trials and have shown that recombinant granulysin is an effective antitumor treatment.

“The two approved projects are based on patent licenses that emanate from this collaboration, one of them with the University of Zaragoza and the other with Harvard Medical School”, says De Gregorio.

The Madrid-based company has agreements with various entities and universities

Peaches Biotech is a company specializing in the creation of medicines based on advanced therapies, especially with cytokines, stem cells, or T-lymphocytes, which will allow patients to take advantage of new therapeutic options.

The company’s main areas of research work are selective rich plasma (PRS), a patent-based process developed by Peaches Biotech that generates a suite of cytokines selective for various tissues, and opT cells, a process based on a license from Peaches Biotech for the treatment of pancreatic cancer.

The Madrid-based company has agreements with various entities and universities. At the Madrid center, Peaches Biotech develops a bio incubator oriented towards research and innovation (R&D) and its objective is to promote translational projects in the areas of oncology, hematology, and advanced therapies. At Harvard,  the biotech collaborates in pancreatic cancer research.

The company has more than forty workers and, apart from its headquarters in Madrid, it has a laboratory in Fuenlabrada. Peaches Biotech plans to open a production plant in Bilbao. 

__

(Featured image by madartzgraphics via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.